The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor cell expression analysis from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).
 
Zachery Reichert
Consulting or Advisory Role - AstraZeneca; Janssen Oncology
Research Funding - AstraZeneca (Inst)
Expert Testimony - Huff Bowell Bailey
 
Maha Hussain
Honoraria - Academic CME; AstraZeneca; AstraZeneca; Bayer; Bayer; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Novartis; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Novartis; Pfizer; Tango Therapeutics; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Bayer
 
Jennie Lovett
No Relationships to Disclose
 
Masha Kocherginsky
Honoraria - Bristol Myers Squibb Foundation
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Channing Paller
Consulting or Advisory Role - AstraZeneca; Bayer; Dendreon; Exelixis; Janssen Oncology; Omnitura; Pfizer
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Nabil Adra
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Merck; Sanofi
Research Funding - Exelixis (Inst); Genentech (Inst); Merck (Inst); Natera (Inst)
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Dendreon; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Dendreon; Sanofi
 
Joel Picus
Research Funding - lava therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Russell Szmulewitz
Consulting or Advisory Role - Amgen; Bayer; Eisai; Janssen Oncology; Merck; Novartis; Sanofi
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Merck (Inst); Novartis (Inst); Nurix (Inst); Progenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - DAVA Oncology
 
Timothy Kuzel
Honoraria - Bristol Myers Squibb Foundation; Cardinal Health; CVS; EnGeneIC; Fidia Farmaceutici S. p. A.; Janssen Research & Development; Kyowa Kirin International; Merck; Pfizer; SeaGen; Sun Pharma
Consulting or Advisory Role - enGene
Speakers' Bureau - Genomic Health
Patents, Royalties, Other Intellectual Property - Up to Date Section editor on cutaneous lymphomas
Other Relationship - Janssen Research & Development; Sun Pharma
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Latifa Bazzi
No Relationships to Disclose
 
Young Whang
Research Funding - Amgen (Inst); Arvinas (Inst); Clovis Oncology (Inst); Novartis (Inst)
 
Ryan Stephenson
No Relationships to Disclose
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AVEO; Bayer; Gilead Sciences; Janssen Oncology; Macrogenics; Merck; Pfizer
Research Funding - Arvinas (Inst); Exelixis (Inst); Seagen (Inst)
 
Daniel Shevrin
Consulting or Advisory Role - Astellas Pharma
 
Matthew Rettig
Consulting or Advisory Role - INMune Bio
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Arvinas (Inst); Fortis (Inst); Novartis (Inst); Progenics
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Emmanuel Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
 
Todd Morgan
Consulting or Advisory Role - ClevelandDx; Foundation Medicine; Stratify Genomics; Tempus
Research Funding - MDxHealth (Inst)